

THERAPEUTIC APPLICATIONS OF BIOMARKERS IN HEART DISEASES

Miss Bangmayee Dash

Assistant Professor, School of Paramedical & Allied Sciences, DRIEMS University, Cuttack

Corresponding Author: bangmayeedash@driems.ac.in

This review article suggests the recent application of various novel biomarkers for determining various heart treatments and informs a few vital research expansions in this field, for the reason that proper identification and ministrations of persons with severe cardiovascular disease, these biomarkers show a significant role, observed with the help of combination of gist specific troponins with modern worldwide applicable rules for persons suffering from severe heart disorders, but also treatment of myocardial infarction. Apart from this, there is an urgent requirement to develop early biochemical markers that can detect myocardial ischemia. Based on the biochemical analysis, there are two types of indicators: biomarkers for lack of blood supply to any parts of body and biochemical molecules for inflammation. With the help of genomics and proteomics, the utilization of biochemical markers for the treatment is increasing rapidly. This paper reviews the application of BNP, GDF-15, serum uric acid, troponins, and many more.

Keywords: Biomarkers, Peptides, Acute coronary syndrome, and myocardial infarction.

Introduction:

Over the past 1.2 years, the importance of clinical cardiology in combination with Laboratory Medicine has increased, as compared to 20 years ago when cardiologists used to detect cardiac tissue necrosis by using addition of phosphate group in creatine and dehydrogenation properties of lactose [1]. Based on modern science and technology, myocardial damage can be easily detected by using cardiac troponins, along with various biochemical markers, and cardiac natriuretic peptides, which are based on current guidelines related to myocardial infarction.

Biomarkers of MI:

According to WHO, clinical presentation, alteration in the ECG, and enhanced the parameters of “cardiac” biocatalyst, CK-MB properties are the primary 3 parameters in detecting myocardial necrosis[2].

According to the USA College of Cardiology and the Joint European Society of Cardiology created a novel definition for this disorder, which is associated with increased levels of biochemical identifiers of heart diseases combined the formation of Q waves[3]. Furthermore, a novel biomarker used in the treatment of myocardial necrosis is cardiac troponins, it is effective due to its sensitive properties towards myocardial injury and is highly specific towards the damage of the heart. Which can be used for quantitative analysis small amount, which require 4–10 h after symptom present in the plasma serum. For the treatment of long term conditions, serial troponin measurements can be used for the diagnosis which depends on the concentration of the biochemical markers[4]. MI can be defined as the presence of cardiac troponin which is not including its biochemical mechanism. The impact of Various concentrations of troponin on non- ischaemic pathophysiological conditions is shown in table no 1[5].

Sl.no	Various factors affecting the formation troponins in Cardiac disorders
1	Cardiac trauma
2	Congestive heart failure
3	Discreasing Level of Glycogen
4	End-stage renal failure
5	Haemoglobinopathy with transfusion haemosiderosis
6	Cardiotoxicity from cancer therapy
7	Pulmonary embolism

[Various concentrations of troponin in Heart Disease] [Table no 1][5]

Based on the current publication has discovered the treatment of detecting various heart disease in the existence of unrectifiable destruction[6]. By using biomarkers we could also be able to differentiate nonischaemia and acute MI, which is involved in increasing the level of various biocatalyst presence in heart. The obtained enhanced in lipids bound to Protein (FFAu) in the blood with acute myocardial ischemia has recently been observed for the fast identification of cardiac injury. Another biochemical marker utilized for the therapy of coronary artery disorder

inflammation is C-reactive protein[7]. Various biomarkers used in the treatments of heart diseases are explained in the table below [8].

Biomarker	Guideline	COR	Setting
Natriuretic peptides	ACC/AHA	I	Support diagnosis or exclusion of HF
		I	Prognosis: ambulatory and acute settings
		I	Prognosis: admission levels for ADHF
		IIa	Ambulatory HF: achieve GDMT
		IIa	Prevention: incident of LVD or new-onset HF
		IIb	Acute HF: guide for ADHF medical therapy
	ESC	Diagnosis: rule out HF	
Myocardial injury	ACC/AHA	I	Additive risk stratification: ambulatory, acute
		Ic	Diagnosis: suspected acute HF
	ESC	Ic	Diagnosis: suspected acute HF
Myocardial fibrosis	ACC/AHA	IIb	Additive risk stratification: ambulatory, acute

[Guidelines for Biomarkers] [Table no 02] [8]

Established and emerging biomarkers in heart failure

Heart failure properties can be identified by using protein identifier along with their pathological studies, various biochemical properties, infections. Table 3 gives the classification of the main group and subgroup of myocardial insult[9,10,11].

Main group	Subgroup	Biomarker
Myocardial insult	Myocyte stretch	ANP, BNP, ^a NT-proBNP, ^a MR-proANP, GDF-15, neuregulin
	Myocardial injury	Troponin T, ^a Troponin I, ^a hsTN, heart type fatty acid protein, myosin light-chain kinase 1, creatinine kinase MB fraction
	Oxidative stress	Myeloperoxidase, MR-proADM, oxidized low-density lipoprotein, urinary biopyrrins, plasma malondialdehyde
Neurohormonal-Activation	Renin-angiotensin system	Renin, angiotensin II, aldosterone
	Sympathetic nervous system	Norepinephrine, chromogranin A
	Arginine vasopressin system	Arginine vasopressin, Copeptin
	Endothelin	Endothelin-1, big proET-1
Myocardial-Remodeling	—	Chromogranin A and B
	Inflammation	C-reactive protein, TNF- α , Fas (APO-1), interleukins 1, 6, and 18, cytokines, procalcitonin, adipokines, adiponectin
	Hypertrophy/fibrosis	Soluble ST2, ^a Galectin-3, ^a matrix metalloproteinases, collagen peptide

[Biomarkers for heart failure] [Table no – 3][9,10,11]

GDF-15 is one of the major biomarkers, which is belongs to cytokine super family and used as an essential enzyme for heart failure.[12,13,14]. Various biomarkers used in the treatment of many heart diseases are shown below[15,16,17].

Sl.no	Biomarker Name	Category	Utilization	Ref
1	Troponin	Myocyte injury	Diagnosis of enhanced levels of brain natriuretic peptide, to study the rate of blood flow in blood vessels.	18
2	Brain Natriuretic peptide molecules	Myocyte stretch	Early detection of acute dyspnea.	19
3	Growth differentiation Factor-15	Myocyte stretch	Used to detect early heart failure	20
4	Serum uric acid	Oxidative stress	Hyperuricemia is combined with GDF-15 to identify heart failure.	21
5	Heart-type fatty acid protein	Myocyte injury	Enhanced in this level used to detect cardiomyocyte injuries.	22

[Application of Biomarkers for the treatment of heart diseases] [Table no 3]

Conclusion and Future prospectives:

Developments on molecular biology and genome studies , the focus on regarding analysis of various biomarkers increased now a days, which deals with multifunctional activities and early detection .

References:

- 1.Caporali, A., Anwar, M., Devaux, Y. *et al.* Non-coding RNAs as therapeutic targets and biomarkers in ischaemic heart disease. *Nat Rev Cardiol* **21**, 556–573 (2024). <https://doi.org/10.1038/s41569-024-01001-5>.

2. Biomarkers in Acute Cardiac Disease The Present and the Future Allan S. Jaffe, MD,* Luciano Babuin, MD,* Fred S. Apple, PHD† Rochester and Minneapolis, Minnesota. *Journal of the American College of Cardiology* Vol. 48, No. 1, 2006 © 2006 by the American College of Cardiology Foundation Published by Elsevier Inc. doi:10.1016/j.jacc.2006.02.056.
3. Krauser DG, Lloyd-Jones DM, Chae CU, et al. Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. *Am Heart J* 2005;149:744–50.
4. Topol EJ, Nissen SE. Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in Ischemic heart disease. *Circulation* 1995;92:2333–42.
5. Miller WL, Hartman KA, Burritt MF, Borgeson DD, Burnett JC Jr., Jaffe AS. Biomarker responses during and after treatment with nesiritide infusion in patients with decompensated chronic heart failure. *Clin Chem* 2005;51:569–77.
6. Smith SC Jr., Anderson JL, Cannon RO 3rd, et al. CDC/AHA workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice: report from the clinical practice discussion group. *Circulation* 2004;110:e550–3.
7. Pelsers MM, Hermens WT, Glatz JF. Fatty acid-binding proteins as plasma markers of tissue injury. *Clin Chem Acta* 2005;352:15–35.
8. Gibler WB, Cannon CP, Blomkalns AL, et al. Practical implementation of the guidelines for unstable angina/non-ST-segment elevation myocardial infarction in the emergency department: a scientific statement from the American Heart Association Council on Clinical Cardiology (Subcommittee on Acute Cardiac Care), Council on Cardiovascular Nursing, and Quality of Care and Outcomes Research Interdisciplinary Working Group, in Collaboration With the Society of Chest Pain Centers. *Circulation* 2005;111:2699–710.
9. Eggers KM, Oldgren J, Nordenskjold A, Lindahl B. Diagnostic value of serial measurement of cardiac markers in patients with chest pain: limited value of adding myoglobin to troponin I for exclusion of myocardial infarction. *Am Heart J* 2004;148:574–81.
10. Luepker RV, Apple FS, Christenson RH, et al. Case definitions for acute coronary heart disease in epidemiology and clinical research studies: a statement from the AHA Council on Epidemiology

and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; the European Society of Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; and the National Heart, Lung, and Blood Institute. *Circulation* 2003;108:2543–9.

11. Hamm CW, Goldmann BU, Heeschen C, Kreymann G, Berger J, Meinertz T. Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. *N Engl J Med* 1997;337:1648–53.

12. Myocardial infarction redefined—a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. *Eur Heart J* 2000;21:1502–13.

13. Panteghini M, Gerhardt W, Apple FS, Dati F, Ravkilde J, Wu AH. Quality specifications for cardiac troponin assays. *Clin Chem Lab Med* 2001;39:175–9.

14. Zimmers TA et al (2006) Growth differentiation factor-15: induction in liver injury through p53 and tumor necrosis factor independent mechanisms. *J Surg Res* 130(1):45–5.

15. Mantel A et al (2017) Association between rheumatoid arthritis and risk of ischemic and nonischemic heart failure. *J Am Coll Cardiol* 69(10):1275–1285.

16. Welsh P et al (2018) Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study. *Eur J Heart Fail* 20(2):268–277.

17. Kitai T et al (2017) Circulating intestinal fatty acid-binding protein (I-FABP) levels in acute decompensated heart failure. *Clin Biochem* 50(9):491–495.

18. Maisel AS et al (2002) Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. *N Engl J Med* 347(3):161–167.

19. Otaki Y et al (2014) Association of heart-type fatty acid-binding protein with cardiovascular risk factors and all-cause mortality in the general population: the Takahata study. *PLoS One* 9(5):e94834.

20. van Vark LC et al (2017) Prognostic value of serial galectin-3 measurements in patients with acute heart failure. *J Am Heart Assoc* 6(12):e003700.

21. Costa V et al (2013) RNA-Seq and human complex diseases: recent accomplishments and future perspectives. *Eur J Hum Genet* 21(2):134.

22. Otaki Yet al (2017) Association of plasma xanthine oxidoreduc tase activity with severity and clinical outcome in patients with chronic heart failure. *Int J Cardiol* 228:151–157.

